XML 50 R36.htm IDEA: XBRL DOCUMENT
v3.23.1

Note 14 - Segment Data (Tables) | 12 Months Ended
--- | ---
Mar. 31, 2023
Notes Tables |
Schedule of Segment Reporting Information, by Segment [Table Text Block] |
|  | Year Ended March 31, |
|  | 2023 |  |  | 2022 |  |  | 2021 |
Revenues (a): |  |  |  |  |  |  |  |  |  |  |  |
Clinical Genomics |  | $ | 62,299 |  |  | $ | 32,840 |  |  | $ | - |
Sterilization and Disinfection Control |  |  | 64,609 |  |  |  | 59,044 |  |  |  | 53,119 |
Biopharmaceutical Development |  |  | 47,365 |  |  |  | 45,579 |  |  |  | 33,892 |
Calibration Solutions |  |  | 44,807 |  |  |  | 46,872 |  |  |  | 46,926 |
Reportable segment revenues |  |  | 219,080 |  |  |  | 184,335 |  |  |  | 133,937 |
Corporate and Other (b) |  |  | - |  |  |  | - |  |  |  | - |
Total revenues |  | $ | 219,080 |  |  | $ | 184,335 |  |  | $ | 133,937 |
Gross profit: |  |  |  |  |  |  |  |  |  |  |  |
Clinical Genomics |  | $ | 32,485 |  |  | $ | 11,941 |  |  | $ | - |
Sterilization and Disinfection Control |  |  | 46,520 |  |  |  | 43,720 |  |  |  | 39,870 |
Biopharmaceutical Development |  |  | 30,340 |  |  |  | 28,605 |  |  |  | 21,035 |
Calibration Solutions |  |  | 24,388 |  |  |  | 24,989 |  |  |  | 26,112 |
Reportable segment gross profit |  |  | 133,733 |  |  |  | 109,255 |  |  |  | 87,017 |
Corporate and Other (b) |  |  | (40 | ) |  |  | (165 | ) |  |  | (3 | )
Gross profit |  | $ | 133,693 |  |  | $ | 109,090 |  |  | $ | 87,014 |
Reconciling items: |  |  |  |  |  |  |  |  |  |  |  |
Operating expenses |  |  | 130,373 |  |  |  | 104,388 |  |  |  | 74,656 |
Operating income |  |  | 3,320 |  |  |  | 4,702 |  |  |  | 12,358 |
Nonoperating expense |  |  | 3,709 |  |  |  | 1,128 |  |  |  | 10,055 |
Earnings before income taxes |  | $ | (389 | ) |  | $ | 3,574 |  |  | $ | 2,303 |
Schedule of Segment Reporting Information, by Inventory Segment [Table Text Block] |
|  | March 31, |  |  | March 31, |
|  | 2023 |  |  | 2022 |
Clinical Genomics |  | $ | 13,985 |  |  | $ | 11,802 |
Sterilization and Disinfection Control |  |  | 3,492 |  |  |  | 2,176 |
Biopharmaceutical Development |  |  | 8,384 |  |  |  | 4,495 |
Calibration Solutions |  |  | 8,781 |  |  |  | 6,133 |
Reportable segment inventory |  |  | 34,642 |  |  |  | 24,606 |
Corporate and Other |  |  | - |  |  |  | - |
Total inventories, net |  | $ | 34,642 |  |  | $ | 24,606 |
Long-Lived Assets by Geographic Areas [Table Text Block] |
|  | As of March 31, |
|  | 2023 |  |  | 2022 |
United States |  | $ | 34,729 |  |  | $ | 36,475 |
Foreign |  |  | 3,793 |  |  |  | 3,975 |
Total |  | $ | 38,522 |  |  | $ | 40,450 |
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] |
|  | Year Ended March 31, |
|  | 2023 |  |  | 2022 |  |  | 2021 |
United States |  | $ | 117,281 |  |  | $ | 99,068 |  |  | $ | 71,387 |
China |  |  | 25,797 |  |  |  | 16,518 |  |  |  | 6,612 |
Other |  |  | 76,002 |  |  |  | 68,749 |  |  |  | 55,938 |
Total revenues |  | $ | 219,080 |  |  | $ | 184,335 |  |  | $ | 133,937 |

X
- Definition A table disclosing the inventory totals for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment inventory reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment inventory. + References No definition available. + Details
Name: | mlab_ScheduleOfSegmentReportingInformationByInventorySegmentTableTextBlock
Namespace Prefix: | mlab_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph b -SubTopic 10 -Topic 280 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration